ABCL-207 Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
Clinical Lymphoma Myeloma and Leukemia（2024）
关键词
ABCL,aggressive B-cell lymphoma,diffuse large B-cell lymphoma,immunotherapy,real-world,tafasitamab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要